ARS Pharma updates corporate presentation for Q4 2023 investor meetings

ARS Pharmaceuticals, Inc.

Company posted updated corporate presentation on its website and furnished as Exhibit 99.1.
Presentation covers pipeline, clinical data, and commercial strategy for neffy (epinephrine nasal spray).
No financial updates or forward guidance included in the filing or presentation summary provided.
Presentation is furnished under Regulation FD; not incorporated by reference into SEC filings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.